CTRS is above all a wonderful medical, pharmaceutical, industrial and human story.

The company was founded in 2002 by a group of friends from healthcare area and who shared the same values. From the very beginning of our adventure, we wanted to work in collaboration with academic structures. Research gives rise to incredibly innovative and very high-quality products. Yet, it too often stops at the clinical research stage, leaving thousands of patients without hope of a cure being found. 

At CTRS, our ambition is to serve as the missing link between these discoveries and patients. We are particularly involved in the field of rare diseases: this area has its specificities and necessarily requires working at a global level. Although the path is difficult, long et complex, we adapted CTRS’ structure giving a crucial role to medical and regulatory departments. We are proud to have proven that by going out from pre-established models, it became possible to develop new, effective and safe treatments even where the number of patients is extremely low. 

We fully believe in public-private partnerships. In more than fifteen years, we have signed several partnerships with the Assistance Publique des Hôpitaux de Paris, the Saint-Joseph Hospital and the Imagine Foundation. Our collaborations are an example of effective long terms partnerships:  by working hand-by-hand with academic teams, we not only bring a product on market, but we continue to advance medical knowledge post approval. This complementary expertise and knowledge sharing is certainly one of our key factors of success.

We hope that the coming years will lead to new collaborations with other academic teams in France and Europe as well as with other structures. We will thus be able to continue to provide patients with new products, especially where the existing therapeutic approaches are insufficient or non-existent.

I would like to thank everyone who has believed in our vision and has put its trust on us: clinicians, researchers, patient organisations, partners, and of course the entire CTRS team.